Open access
Open access
Powered by Google Translator Translator

Covid-19

Compared with previous waves, the Omicron wave in South Africa was associated with fewer hospitalizations and decreased severity and mortality.

8 Jan, 2022 | 23:23h | UTC

Characteristics and Outcomes of Hospitalized Patients in South Africa During the COVID-19 Omicron Wave Compared With Previous Waves – JAMA

 

[Preprint] RCT: In symptomatic adults above 18 years positive for SARS-CoV-2, early outpatient treatment with high-titer convalescent plasma significantly reduced hospitalizations.

8 Jan, 2022 | 23:28h | UTC

Randomized Controlled Trial of Early Outpatient COVID-19 Treatment with High-Titer Convalescent Plasma – medRxiv

News release: Early Use of Convalescent Plasma May Help Outpatients with COVID-19 Avoid Hospitalization – Johns Hopkins Medicine

Commentary: Convalescent plasma shows renewed promise for COVID-19 in outpatient trial – Science

 

[Preprint] Study showed reduced clinical severity of Covid-19 patients admitted to hospitals in Gauteng, South Africa, during the Omicron-dominant fourth wave – “any combination of a less-virulent virus, comorbidities, high immunity from prior infection(s) or vaccination may be important contributors to this clinical presentation”.

8 Jan, 2022 | 23:24h | UTC

Clinical Severity of COVID-19 Patients Admitted to Hospitals in Gauteng, South Africa During the Omicron-Dominant Fourth Wave – SSRN/Preprints with The Lancet

Commentary: SARS-CoV-2 omicron variant may be less severe than the delta variant – News Medical

 

AAP Interim guidance on supporting the emotional and behavioral health needs of children, adolescents, and families during the COVID-19 pandemic.

17 Dec, 2021 | 09:57h | UTC

Interim Guidance on Supporting the Emotional and Behavioral Health Needs of Children, Adolescents, and Families During the COVID-19 Pandemic – American Academy of Pediatrics

Commentary: AAP Issues Guidance for Children’s Emotional Needs During COVID-19 – HealthDay

 

RCT: Among patients hospitalized with COVID-19 at increased risk for venous thromboembolism, post-discharge thromboprophylaxis with Rivaroxaban for 35 days may improve outcomes.

17 Dec, 2021 | 09:50h | UTC

Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial – The Lancet

Invited commentary: Anticoagulation in COVID-19 – The Lancet

 

Commentary on Twitter

 

RCT: Molnupiravir reduced the risk of hospitalization or death in at-risk (i.e., obesity, over 60 years, etc.) unvaccinated adults with Covid-19.

17 Dec, 2021 | 09:52h | UTC

Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients – New England Journal of Medicine

Related: Merck’s COVID pill loses its lustre: what that means for the pandemic – Nature (several articles on the subject)

 

WHO issues interim recommendations for heterologous COVID-19 vaccine schedules.

17 Dec, 2021 | 10:01h | UTC

Interim recommendations for heterologous COVID-19 vaccine schedules – World Health Organization

Commentary: Coronavirus: WHO gives the nod for mix-and-match vaccine schedules – South China Morning Post

 

Randomized trial with nearly 30.000 individuals showed Novavax vaccine was safe and had an overall efficacy of 90.4% against symptomatic infections.

17 Dec, 2021 | 09:54h | UTC

Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico – New England Journal of Medicine

Commentaries:

Novavax COVID vaccine shows 90.4% efficacy against infection – CIDRAP

Novavax COVID-19 vaccine found to be safe and effective – University of Maryland School of Medicine

Related: [Preprint] In RCT with 29,949 participants, the Novavax vaccine demonstrated high overall efficacy (>90%) for the prevention of Covid-19, and all moderate-to-severe cases occurred in placebo recipients. (several articles on the subject)

 

CDC advisors recommend mRNA COVID vaccines over J&J.

17 Dec, 2021 | 09:46h | UTC

CDC advisors recommend mRNA COVID vaccines over J&J – CIDRAP

 

Covid-19: Runny nose, headache, and fatigue are commonest symptoms of Omicron, early data show.

17 Dec, 2021 | 09:48h | UTC

Covid-19: Runny nose, headache, and fatigue are commonest symptoms of omicron, early data show – The BMJ

See also: Omicron and cold-like symptoms rapidly taking over in London – ZOE COVID Study

 

Commentary on Twitter

 

Breakthrough infections generate ‘super immunity’ to COVID-19, study suggests.

17 Dec, 2021 | 09:47h | UTC

News Release: Breakthrough infections generate ‘super immunity’ to COVID-19, study suggests – Oregon Health & Science University

Original Study: Antibody Response and Variant Cross-Neutralization After SARS-CoV-2 Breakthrough Infection – JAMA

 

Opinion: COVID-19 vaccine strategies must focus on severe disease and global equity.

17 Dec, 2021 | 09:45h | UTC

COVID-19 vaccine strategies must focus on severe disease and global equity – The Lancet

 

How COVID vaccines shaped 2021 in eight powerful charts.

17 Dec, 2021 | 09:44h | UTC

How COVID vaccines shaped 2021 in eight powerful charts – Nature

 

Review uncovers weak COVID clinical practice guidelines.

16 Dec, 2021 | 10:31h | UTC

Review uncovers weak COVID clinical practice guidelines – CIDRAP

Original Study: Adherence of Clinical Practice Guidelines for Pharmacologic Treatments of Hospitalized Patients With COVID-19 to Trustworthy Standards: A Systematic Review – JAMA Network Open

 

Commentary on Twitter

 

Modeling COVID-19 mortality across 44 Countries: Face covering may reduce deaths.

16 Dec, 2021 | 10:33h | UTC

Modeling COVID-19 Mortality Across 44 Countries: Face Covering May Reduce Deaths – American Journal of Preventive Medicine

Commentary: Mask laws could prevent unnecessary COVID-19 deaths, study shows – News Medical

 

Autoimmune encephalitis after SARS-CoV-2 infection: case frequency, findings, and outcomes.

16 Dec, 2021 | 09:47h | UTC

Autoimmune Encephalitis After SARS-CoV-2 Infection: Case Frequency, Findings, and Outcomes – Neurology

 

Commentary on Twitter

 

Merck’s COVID pill loses its luster: what that means for the pandemic – “Molnupiravir was initially heralded by public-health officials as a game-changer for COVID-19, but full clinical-trial data showed lower-than-expected efficacy”.

16 Dec, 2021 | 09:52h | UTC

Merck’s COVID pill loses its lustre: what that means for the pandemic – Nature

Related:

FDA panel narrowly recommends authorization of first antiviral pill to treat COVID.

[Press release – not published yet] Merck’s new Covid-19 pill Molnupiravir updated data shows reduced efficacy (30%) for preventing hospitalization and death compared to initial results (50%). Absolute risk reduction of hospitalization and death fell from 7% to 3%.

8 lingering questions about the new Covid pills from Merck and Pfizer.

COVID antiviral pills: what scientists still want to know – “Drugs like Molnupiravir and Paxlovid could change the course of the pandemic if clinical trial results hold up in the real world”.

[Press release – not published yet] RCT: Pfizer’s novel Covid-19 oral antiviral treatment candidate reduced risk of hospitalization or death by 89% in interim analysis of phase 2/3 EPIC-HR study.

A prominent virologist warns new COVID-19 pill could unleash dangerous mutants. Others see little cause for alarm.

The U.K. approves Merck’s COVID-19 antiviral pill, calling it a world first.

Merck to allow other nations to produce new COVID-19 antiviral.

Video: Merck’s Covid pill could transform treatment. Here’s how it works.

How antiviral pill Molnupiravir shot ahead in the COVID drug hunt.

What we know — and don’t know — about Merck’s new Covid-19 pill.

[Press release – not published yet] Merck announces oral antiviral Molnupiravir reduced the risk of hospitalization or death by approximately 50 Percent compared to placebo for patients with mild or moderate COVID-19.

Merck’s Covid-19 pill is great news but may not be a game-changer.

Video | A Pill For COVID? A Doctor Explains Molnupiravir.

 

Opinion: Unequal global vaccine coverage is at the heart of the current covid-19 crisis.

16 Dec, 2021 | 09:50h | UTC

Unequal global vaccine coverage is at the heart of the current covid-19 crisis – The BMJ

 

T Cells might be our bodies’ best shot against Omicron.

16 Dec, 2021 | 09:45h | UTC

T Cells Might Be Our Bodies’ Best Shot Against Omicron – The Atlantic

 

M-A: Global percentage of asymptomatic SARS-CoV-2 infections around 40%.

15 Dec, 2021 | 08:47h | UTC

Global Percentage of Asymptomatic SARS-CoV-2 Infections Among the Tested Population and Individuals With Confirmed COVID-19 Diagnosis: A Systematic Review and Meta-analysis – JAMA Network Open

Commentary: ~40 Percent With Confirmed COVID-19 Are Asymptomatic – HealthDay

 

Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination vs. SARS-CoV-2 infection.

15 Dec, 2021 | 08:43h | UTC

Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection – Nature Medicine

News release: COVID-19 infection, more likely than vaccines, to cause rare cardiovascular complications – University of Oxford

 

Commentaries on Twitter

 

[Press release – not published yet] Pfizer’s Covid pill remains 89% effective for reducing the risk of hospitalization or death in final analysis.

15 Dec, 2021 | 08:46h | UTC

News release: Pfizer announces additional phase 2/3 study results confirming robust efficacy of novel Covid-19 oral antiviral treatment candidate in reducing risk of hospitalization or death

Commentaries:

Pfizer’s Covid pill remains 89% effective in final analysis, company says – STAT

Pfizer confirms COVID pill’s results, potency versus omicron – Associated Press

Related:

8 lingering questions about the new Covid pills from Merck and Pfizer.

COVID antiviral pills: what scientists still want to know – “Drugs like Molnupiravir and Paxlovid could change the course of the pandemic if clinical trial results hold up in the real world”.

[Press release – not published yet] RCT: Pfizer’s novel Covid-19 oral antiviral treatment candidate reduced risk of hospitalization or death by 89% in interim analysis of phase 2/3 EPIC-HR study.

 

Commentary on Twitter (thread – click for more)

 

Rapidly spreading Omicron is now in 77 countries and WHO warns against assuming its effects are mild.

15 Dec, 2021 | 08:39h | UTC

Rapidly Spreading Omicron is Now in 77 Countries and WHO Warns Against Assuming its Effects are Mild – Health Policy Watch

 

Study suggests COVID-19 certificates may boost vaccine uptake in countries with below average coverage.

15 Dec, 2021 | 08:41h | UTC

News Release: COVID-19 certificates may boost vaccine uptake in countries with below average coverage – University of Oxford

Original Study: The effect of mandatory COVID-19 certificates on vaccine uptake: synthetic-control modelling of six countries – The Lancet Public Health

 

Commentary on Twitter

https://twitter.com/ruettenauer/status/1470675353937063937

 

COVID-19 in 2022: controlling the pandemic is within our grasp.

15 Dec, 2021 | 08:36h | UTC

COVID-19 in 2022: controlling the pandemic is within our grasp – Nature Medicine

 

Commentaries on Twitter

 

Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.